News | Peripheral Artery Disease (PAD) | August 24, 2016

Positive TOBA Mini Stent Tacking System One-Year Results Published

First large-scale, multicenter clinical trial data demonstrates safety and efficacy of the Tack Endovascular System

Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery

August 24, 2016 — Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical study were published in the July 2016 edition of the Journal of Vascular Surgery.

The TOBA study enrolled 138 subjects at 13 sites in Europe. All study participants were suffering from peripheral artery disease caused by blockages in the superficial femoral or popliteal arteries, which are located in the upper part of the leg. All participants underwent percutaneous balloon angioplasty (PTA) with any dissections (or tears) resulting from PTA repaired using the Tack Endovascular System.

The Tack implant is a new technology designed to repair dissections in the artery wall that frequently occur as a complication during PTA. The system allows physicians to repair these dissections while leaving a minimal amount of foreign material in the artery, which reduces mechanical stress on the artery; leaves the artery in its most natural state; and preserves future treatment options. If the dissections are left unrepaired, they increase the probability of acute artery occlusion or may continue narrowing the artery.

Some key conclusions from the TOBA study included:

  • 98.5 percent of participants achieved technical success;
  • 76.4 percent 12-month primary patency;
  • 89.5 percent freedom from target lesion revascularization (TLR); and
  • 82.8 percent participants had a Rutherford Classification grade ≤1 at 12 months, representing a significant improvement in function from baseline.

Marc Bosiers, M.D., A.Z. St. Blasius Hospital, Dendermonde, Belgium, was the principal investigator for the TOBA study. Bosiers stated, “These one-year results from the TOBA study demonstrate that the minimal metal approach associated with the Tack implant produces positive, lasting results in patients with severe peripheral artery disease. This is a high-cost, resource-intensive disease, so treatments with long-term effectiveness, such as combining angioplasty with the Tack implant, bring substantial benefits for patients and payers alike.”

Peter Schneider, M.D., chief of vascular at the Kaiser Foundation Hospital in Honolulu, Intact Vascular’s co-founder and chief medical officer, added, “This first, large-scale study investigating the safety and efficacy of the Tack Endovascular System is a key building block for the broad clinical development program we are pursuing at Intact Vascular. Plain PTA in this setting typically has a one-year patency rate of 30-55 percent. When we added the Tack device to the treatment, the one-year success was improved to 76.4 percent. Our next studies involve combining the Tack system with drug-coated balloon angioplasty, which is the focus of our TOBA II and III clinical trials.”

Based on these results, Intact Vascular has been enrolling participants in an expanded study, TOBA II  that is being conducted at more than 35 U.S. and European centers under an Investigational Device Exemption (IDE) approval. The company plans to submit data from TOBA II in support of a pre-market approval application with the U.S. Food and Drug Administration (FDA).

Recently, the company commenced enrollment in TOBA III, a post-CE Mark study conducted in Europe to assess the combination of the Tack implant and drug-coated balloon angioplasty in the superficial femoral and popliteal arteries.

For more information: www.intactvascular.com

Related Content

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major
TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th